Clearline Capital’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Clearline Capital’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,024	Closed	-$109K	–	142
2022 Q4	$109K	Sell	250,024 -142,667	-36%	-$46.3K	0.02%	116
2022 Q3	$110K	Hold	392,691	–	–	0.01%	133
2022 Q2	$141K	Hold	392,691	–	–	0.02%	127
2022 Q1	$263K	Buy	392,691 +174,185	+80%	+$148K	0.03%	117
2021 Q4	$282K	Buy	+218,506	New	+$388K	0.03%	124

Other funds holding SIOX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Clearline Capital's SIOX Position: Q1 2023 in Review

Clearline Capital sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 250,024 shares — an estimated $109K sold.

Clearline Capital first reported a position in SIOX in Q4 2021 and held it in 5 quarters. The position peaked at $282K in Q4 2021. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

Clearline Capital reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Clearline Capital sold 250,024 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $109K.
Clearline Capital first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Clearline Capital's Sio Gene Therapies Inc. Common Stock position peaked at $282K in Q4 2021.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Clearline Capital's 13F filing for Q1 2023, filed 15 May 2023.